{"id":"W2979282408","doi":"10.1093/annonc/mdz251.039","title":"DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Open label; Refractory (planetary science); Phases of clinical research; Oncology; Open label study; Internal medicine; Safety profile; Clinical trial; Adverse effect; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00179483,0.001664098,0.002632206,0.0006351798,0.0004500778,0.001109397,0.001262682,0.00144103,0.006148191],"category_scores_gemma":[0.0008434372,0.0007733569,0.002009619,0.0003701923,0.001213215,0.001347696,0.0004672848,0.004160807,0.001488628],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001222106,"about_ca_system_score_gemma":0.002027318,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009515043,"about_ca_topic_score_gemma":0.002952627,"domain_scores_codex":[0.9995303,0.0002034715,0.0000238686,0.00008366022,0.00004798026,0.0001106632],"domain_scores_gemma":[0.9994992,0.00006900559,0.0001081687,0.00005906229,0.00002853207,0.000236031],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7750273,0.07692101,0.002849404,0.001614247,0.002272484,0.000153434,0.0002749155,0.002773099,0.04028061,0.000584154,0.004991017,0.09225839],"study_design_scores_gemma":[0.661689,0.3265866,0.003685822,0.00004409034,0.0005904479,0.0001773184,0.00006021551,0.001102627,0.002709643,0.0003419966,0.002970658,0.00004165688],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9864227,0.003377212,0.00113997,0.0006839243,0.0002399185,0.003417323,0.002092901,0.0003012813,0.00232482],"genre_scores_gemma":[0.9752485,0.002911844,0.005099854,0.001461225,0.0002458302,0.005785985,0.003516456,0.0000725256,0.005657694],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006148191,"threshold_uncertainty_score":0.02056772,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1719323476661138,"score_gpt":0.4441159285926465,"score_spread":0.2721835809265327,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}